Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)

被引：29
|
作者：
Attar, Eyal C. [1 ]
Amrein, Philip C. [1 ]
Fraser, James W. [1 ]
Fathi, Amir T. [1 ]
McAfee, Steven [1 ]
Wadleigh, Martha [2 ]
DeAngelo, Daniel J. [2 ]
Steensma, David P. [2 ]
Stone, Richard M. [2 ]
Foster, Julia [1 ]
Neuberg, Donna [3 ]
Ballen, Karen K. [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Ctr Leukaemia, Boston, MA USA
[2] Dana Farber Canc Inst, Adult Leukemia Program, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷 / 09期
关键词：
Bortezomib and lenalidomide in MDS and AML; ACUTE MYELOGENOUS LEUKEMIA; INTERNATIONAL WORKING GROUP; RESPONSE CRITERIA; STEM-CELLS; KAPPA-B; THERAPY; RISK; CYTARABINE; INDUCTION; DELETION;
D O I：
10.1016/j.leukres.2013.05.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We conducted a phase I dose escalation study to determine the maximal tolerated dose of bortezomib that could be combined with standard dose lenalidomide in patients with MDS or AML. Treatment consisted of bortezomib (IV) on Days 1, 4, 8, and 11 and lenalidomide 10 mg daily (PO) days 1-21 in 28 day cycles for up to 9 cycles. 23 patients (14 MDS/CMML, 9 AML) were enrolled. The maximally tested dose of bortezomib, 1.3 mg/m(2), was tolerable in this regimen. Responses were seen in patients with MDS and AML. Further testing of this regimen is planned. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1016 / 1020
页数：5
相关论文
共 50 条
  • [1] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Amrein, Philip C.
    Attar, Eyal C.
    Fathi, Amir Tahmasb
    McAfee, Steven L.
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Steensma, David P.
    Foster, Julia
    Stone, Richard M.
    Neuberg, Donna S.
    Ballen, Karen K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
    Navada, S. C.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Azarnia, N.
    Silverman, L. R.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S45 - S45
  • [3] Low dose Vidaza and thalidomide is an effective combination for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
    Westervelt, P.
    Amirifeli, S.
    Mehdi, M.
    Mumtaz, M.
    Alhomsi, S.
    Wang, S.
    Miron, P.
    Lata, C.
    Galili, N.
    Raza, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 354S - 354S
  • [4] Phase I Study of Bortezomib Combined with Lenalidomide for Relapsed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Following Hematopoietic Cell Transplantation
    Brunner, Andrew M.
    Blonquist, Traci M.
    McMasters, Malgorzata
    Hobbs, Gabriela S.
    McAfee, Steven L.
    Rosenblatt, Jacalyn
    Amrein, Philip C.
    El-Jawahri, Areej
    Connolly, Christine
    Ramos, Aura
    Mikami, Kaleb
    Logan, Emma
    Dey, Bimalangshu R.
    Spitzer, Thomas
    Avigan, David E.
    Fathi, Amir T.
    Chen, Yi-Bin
    Ballen, Karen
    [J]. BLOOD, 2017, 130
  • [5] Diagnostic of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Germing, Ulrich
    Haferlach, Torsten
    [J]. LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2015, 39 (05): : 291 - 299
  • [6] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    [J]. BLOOD, 2014, 124 (21)
  • [7] CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY
    Steensma, D.
    Abedi, M.
    Bejar, R.
    Cogle, C.
    Foucar, K.
    Garcia-Manero, G.
    George, T.
    Grinblatt, D.
    Komrokji, R.
    Maciejewski, J.
    Pollyea, D.
    Roboz, G.
    Savona, M.
    Scott, B.
    Sekeres, M.
    Thompson, M.
    Sugrue, M.
    Swern, A.
    Nifenecker, M.
    Erba, H.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S124 - S124
  • [8] Phase II study of Mylotarg plus Troxatyl in patients with refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
    Giles, FJ
    Garcia-Manero, G
    O'Brien, S
    Estey, E
    Kantarjian, H
    [J]. BLOOD, 2001, 98 (11) : 212B - 212B
  • [9] Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients
    Rollison, Dana E.
    Shain, Kenneth H.
    Lee, Ji-Hyun
    Hampras, Shalaka S.
    Fulp, William
    Fisher, Kate
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey
    Xu, Qiang
    Knight, Robert D.
    List, Alan F.
    Dalton, William
    Komrokji, Rami
    [J]. BLOOD, 2014, 124 (21)
  • [10] A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    DiNardo, Courtney D.
    Olin, Rebecca
    Ishizawa, Jo
    Sumi, Hiroyuki
    Xie, Jingdong
    Kato, Kazunobu
    Kumar, Prasanna
    Andreeff, Michael
    [J]. BLOOD, 2019, 134
12345